• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Becton Dickinson and Company

    6/4/24 5:26:24 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email
    FWP 1 ny20030306x7_fwp.htm FWP
    Filed pursuant to Rule 433
    Issuer Free Writing Prospectus dated June 4, 2024 Supplementing the Preliminary Prospectus Supplement dated June 4, 2024
    Registration Statement No. 333-279084-01
    333-279084
     

    Pricing Term Sheet
     
    Becton Dickinson Euro Finance S.à r.l.
    €800,000,000 4.029% Notes due 2036
    (the “Notes”)

    Fully and Unconditionally Guaranteed by
    Becton, Dickinson and Company

    Issuer:
    Becton Dickinson Euro Finance S.à r.l. (the “Company”)

    Guarantor:
    Becton, Dickinson and Company (the “Guarantor”)
       
    Aggregate Principal Amount Offered:
    €
    800,000,000
         
    Maturity Date:
    June 7, 2036
       
    Trade Date:
    June 4, 2024
       
    Settlement Date:
    June 7, 2024 (T+3)*
       
    Type of Offering:
    SEC Registered
       
    Coupon (Interest Rate):
    4.029%
         
    Price to Public (Issue Price):
    100.000% of principal amount
       
    Underwriting Discount:
    0.500%
         
    Yield to Maturity:
    4.029%
         
    Spread to Benchmark German Government Security:
    +141.9 basis points
       
    Benchmark German Government Security:
    0.000% DBR due May 15, 2036
       
    Benchmark German Government Security Price/Yield:
    73.515% / 2.610%
         
    Mid-Swap Yield:
    2.779%
         
    Spread to Mid-Swap Yield:
    +125 basis points
       
    Interest Payment Dates:
    Annually, on June 7, commencing June 7, 2025
       
    Day Count Convention:
    ACTUAL/ACTUAL (ICMA)

       
    Optional Redemption:
    The Notes will be redeemable at the Company’s option, in whole or in part, at any time and from time to time prior to March 7, 2036 (three months prior to the maturity date), at a redemption price equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments on the Notes being redeemed, discounting such payments to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable comparable government bond rate, plus 25 basis points, plus, in each case, accrued and unpaid interest thereon to, but excluding, the redemption date.
     
    At any time on or after March 7, 2036 (three months prior to the maturity date), the Notes will be redeemable at the Company’s option, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date.
     
       
    Redemption for Tax Reasons:
    If, as a result of any change in, or amendment to, the tax laws of a Taxing Jurisdiction (as defined in the preliminary prospectus supplement), or the official interpretation thereof, the Company becomes or, based upon a written opinion of independent counsel selected by the Company, will become obligated to pay additional amounts with respect to the Notes, the Company may at any time at its option redeem, in whole, but not in part, the Notes at 100% of the principal amount plus accrued and unpaid interest to the date of redemption.
       
    Special Mandatory Redemption:
    If (i) the Acquisition is not consummated on or before the Special Mandatory Redemption End Date or (ii) the Guarantor notifies the trustee under the indenture that it will not pursue the consummation of the Acquisition, the Issuer will be required to redeem the Notes at a special mandatory redemption price equal to 101% of the aggregate principal amount of the Notes, plus accrued and unpaid interest, if any, to, but excluding, the special mandatory redemption date.
       
    Change of Control:
    If a change of control triggering event occurs, unless the Company has exercised its right to redeem the Notes as described under “Optional Redemption,” the Company will be required to make an offer to each holder of the outstanding Notes to repurchase all or any portion of such holder’s Notes at a purchase price of 101% of the principal amount plus accrued and unpaid interest to, but excluding, the date of purchase.
       
    Form/Clearing Systems:
    The Notes will be issued only in registered, book-entry form. There will be a global Note for each series of Notes deposited with a common safekeeper for Euroclear and Clearstream.
       
    Listing:
    Application will be made to have the Notes listed on Euronext Dublin for trading on the Global Exchange Market.
    2

       
    Concurrent Offering:
    Concurrently with this offering, the Guarantor is offering €1,000,000,000 aggregate principal amount of 3.828% Notes due 2032 (the “Concurrent Offering”). The Guarantor may, in the near term, also consider pursuing additional capital markets transactions, including potential offerings of U.S. dollar-denominated senior notes.

    The Concurrent Offering is being made by means of a separate prospectus supplement and not by means of the prospectus supplement to which this pricing term sheet relates. This communication is not an offer to sell or a solicitation of an offer to buy any securities being offered in the Concurrent Offering. The closing of this offering and the Concurrent Offering is not conditioned on each other.
       
    New Safekeeping Structure:
    Yes, and the notes are intended to be held in a manner that would allow eligibility as collateral for Eurosystem intra-day credit and monetary policy operations
       
    MiFID II Product Governance:
    Manufacturer target market (MiFID II product governance) is eligible counterparties and professional clients only (all distribution channels)
       
    UK MiFIR Product Governance:
    Manufacturer target market (UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels)
       
    PRIIPs:
    No EU PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in the EEA or in the UK
       
    Common Code/ISIN:
    283892484 / XS2838924848
       
    Denominations:
    €
    100,000 x €1,000
         
    Stabilization:
    Stabilization/FCA
       
    Joint Book-Running Managers:
    Citigroup Global Markets Limited
    Barclays Bank PLC
    BNP Paribas
    J.P. Morgan Securities plc
    Wells Fargo Securities International Limited
    MUFG Securities (Europe) N.V.
    Scotiabank (Ireland) Designated Activity Company
    U.S. Bancorp Investments, Inc.
       
    Co-Managers:
    Academy Securities, Inc.
    ING Bank N.V, Belgian Branch
    Intesa Sanpaolo IMI Securities Corp.
    Loop Capital Markets LLC
    R. Seelaus & Co., LLC
    Siebert Williams Shank & Co., LLC
    Standard Chartered Bank
    The Toronto-Dominion Bank
     
       

    *
    Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the business day preceding the settlement date will be required, by virtue of the fact that the Notes initially settle on the third business day following the Trade Date, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes prior to their date of delivery hereunder should consult their advisors.
    3

    The Guarantor and the Issuer have filed a registration statement with the SEC (including a prospectus and a preliminary prospectus supplement), for the offering to which this communication relates. Before you invest, you should read the prospectus and the preliminary prospectus supplement in that registration statement and other documents the Guarantor and the Issuer have filed with the SEC for more complete information about the Guarantor, the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at http://www.sec.gov. Alternatively, the Issuer, the Guarantor, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting Citigroup Global Markets Limited toll-free at 1-800-831-9146, Barclays Bank PLC toll-free at 1-888-603-5847, BNP Paribas toll-free at 1-800-854-5674, J.P. Morgan Securities plc at +44-20-7134-2468 or Wells Fargo Securities International Limited at +44-20-3942-8530.
     
    This pricing term sheet supplements the preliminary prospectus supplement dated June 4, 2024 relating to the prospectus dated May 2, 2024.  Capitalized terms used in this term sheet but not defined herein have the meanings given to them in the preliminary prospectus supplement.
     
    MiFID II and/or the UK MiFIR Product Governance Rules professionals/ECPs-only / No PRIIPs KID – Manufacturer target market (MIFID II product governance and/or the UK MiFIR Product Governance Rules) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA or the United Kingdom.
     
    Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.
     
    4
    Get the next $BDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX

    DatePrice TargetRatingAnalyst
    2/10/2026$202.00Overweight
    Barclays
    2/3/2026$233.00Buy
    Citigroup
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    5/22/2025$185.00Buy → Neutral
    Citigroup
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    5/2/2025$192.00Buy → Neutral
    Goldman
    5/2/2025Outperform → Mkt Perform
    Raymond James
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $BDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Becton Dickinson & Co disposed of 284,771,350 shares, closing all direct ownership in the company (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Reporting)

    2/11/26 4:17:41 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    New insider Urbini Massimiliano claimed ownership of 4,133 shares (SEC Form 3)

    3 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/6/26 2:31:33 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/5/26 12:24:15 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Henderson Jeffrey William bought $350,430 worth of shares (1,500 units at $233.62), increasing direct ownership by 23% to 8,015 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    2/10/25 5:03:18 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities

    FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series"). Up to an Aggregate Offer Cap of $1,600,000,000 Aggregate Purchase Priceof the Outstanding Debt Securities Listed Below and each Offer SubCap Listed Below Title of Security CUSIP Number Principal Amount Outstanding Offer SubCap Acceptance Priority Level(1) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread Early Ten

    2/10/26 1:00:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation

    FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE:WAT).  In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock that they held as of the close of business on February 5, 2026, the record date for the spin-off, with cash in lieu of any fractional shares of Waters common stock, and BD received $4 billion of cash. As of the closing of the transaction, BD's share

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Becton Dickinson with a new price target

    Barclays resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $202.00

    2/10/26 7:21:54 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Becton Dickinson with a new price target

    Citigroup resumed coverage of Becton Dickinson with a rating of Buy and set a new price target of $233.00

    2/3/26 6:55:14 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/10/26 4:16:23 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Becton Dickinson and Company

    10-Q - BECTON DICKINSON & CO (0000010795) (Filer)

    2/9/26 4:19:27 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    2/9/26 4:18:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors

    FRANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025. "Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and

    11/17/25 4:30:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    Financials

    Live finance-specific insights

    View All

    BD Reports First Quarter Fiscal 2026 Financial Results

    Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, respectivelyCombination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation expected to close todayCompany affirms FY26 revenue growth guidance, provides Adjusted Diluted EPS guidance for New BDFRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered stronger‑than‑expected first‑quarter performance which reflects our disciplined execution

    2/9/26 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

    FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share. The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations pr

    1/27/26 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/16/24 4:29:42 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/14/24 10:02:59 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Becton Dickinson and Company (Amendment)

    SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)

    2/13/24 5:00:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care